Actylis, a global leader in the distribution of critical raw materials for the life sciences industry, has entered into a strategic agreement with Novo Nordisk Pharmatech A/S to distribute pharmaceutical grade benzalkonium chloride (BKC) in key European markets.

Ian Jenning, SVP-President for Europe of Actylis, expressed enthusiasm about the partnership, stating, "This new agreement, based on our existing partnership in North America, represents a great opportunity for Actylis Europe to complete our pharmaceutical portfolio, while supporting the development of the Novo Nordisk Pharmatech BKC for new applications."

The collaboration leverages Novo Nordisk Pharmatech's position as a leading manufacturer of pharmaceutical-grade quaternary ammonium compounds (Quats) and Actylis' expertise and infrastructure in raw material distribution. Together, the companies aim to provide customers in Germany, Spain, Portugal, the United Kingdom, and Ireland with top-tier service and end-to-end quality assurance.

Samia Kappe, Commercial Director of Novo Nordisk Pharmatech A/S, commented, "We are excited to strengthen our collaboration with Actylis, which will extend our high standards to these key European markets. We look forward to a successful partnership in the coming years."